Pipeline

EU307
Indication GPC3 expressing cancer Target /Drug class GPC3 expressing cancer cell / CAR-T Development Stage Non-clinical
Summary
  • 4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T
  • Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo
  • Clear anti-cancer efficacy in an orthotopic model
  • Smaller number of 4th generation GPC3 CAR-T required than other groups to remove HCC
In vitro/in vivo Efficacy
Mode of Action